Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy ...

The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor ... detailing the novel mechanism of action and effectiveness of botensilimab, an ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ... in advanced melanoma patients ineligible for anti-CTLA-4 treatment or ...

and a Prescription Drug User Fee Act target action date of April 21, 2025, was set. 2 CheckMate 9DW is a phase 3, randomized, controlled trial evaluating the combination of nivolumab, a PD-1 inhibitor ...

and a Prescription Drug User Fee Act target action date of April 21, 2025, was set. 2 CheckMate 9DW is a phase 3, randomized, controlled trial evaluating the combination of nivolumab, a PD-1 inhibitor ...

ICI therapy differs from chemotherapy in mechanisms of action and side effect profile ... The less frequent and milder adverse effect profile of PD-1 inhibitors compared to CTLA-4 inhibitors suggests ...